- Novartis (NVS) Q3 core net income -3.1% to $3.1B, almost in line with consensus of $3.12B.
- Core EPS $1.26, below forecasts of $1.29.
- Sales +4% to $14.3B, in line.
- Raises annual forecasts for second time this year and now expects sales to increase at a low- to mid-single-digit percentage rate in constant currencies, and core operating income to match or grow from last year. The reason for the increase is because India's Ranbaxy Laboratories hasn't yet started selling a generic version of Novartis' Diovan blood-pressure drug in the U.S. (PR)
Check out Seeking Alpha’s new Earnings Center »
From other sites
at Zacks.com (Mar 23, 2015)
at Zacks.com (Mar 18, 2015)
at MarketWatch.com (Mar 6, 2015)
at Zacks.com (Mar 5, 2015)
at Nasdaq.com (Feb 27, 2015)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs